Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020

The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others. In addition, various pharmaceutical and biotechnology companies are collaborating with other companies and organizations for R&D of next-generation antibody therapeutics which further drives the market of next-generation antibody therapeutics.

The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020.

The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs.  A significant capital investment is required for the research and manufacturing of next-generation therapeutics. The manufacturing process of next-generation antibody therapeutics is very complex, as it requires specialized equipment and careful handling techniques. Next-generation antibody therapeutics is a biologic product, and thus requires specific downstream process for their production. This leads to the high cost of manufacturing next-generation antibody therapeutics.

Different countries have distinct regulatory requirements for launching a product in the market. Strict regulatory requirements and extended approval time hinders the market for next-generation antibody therapeutics.

The key companies operating in the global next-generation antibody therapeutics market include F. Hoffmann-La Roche Ltd, Seattle Genetics Inc., Pfizer Inc., ImmunoGen Inc., Amgen Inc., Biogen, Kyowa Hakko Kirin Co. Ltd., Xencor Inc., Bristol-Myers Squibb Company, AstraZeneca PLC., Dyax Corp., Takeda Pharmaceuticals Company Limited and Bayer AG.

Report Coverage

• Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis
• Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market
• Uncovers potential demands in the market
• Porter analysis identifies competitive forces within the market
• Provides information on the historical and current market size and the future potential of the market
• Provides sizes of key regional markets using yardsticks of segments, applications, and segments of applications
• Highlights the competitive scenario of the market, major competitors, and benchmarking
• Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.